Literature DB >> 3508715

Two modes of action of bisphosphonates on osteoclastic resorption of mineralized matrix.

P M Boonekamp1, L J van der Wee-Pals, M M van Wijk-van Lennep, C W Thesing, O L Bijvoet.   

Abstract

Pretreatment of a long bone explant with P-C-P can prevent the osteoclastic resorption of its mineralized matrix, when it is entirely dependent upon activation and accession of extra-osseous osteoclast precursors. When treatment of the explant is postponed until after the development of mature osteoclasts, the P-C-P dose required for an inhibitory effect is increased 100-fold for the amino bisphosphonate APD, but not for EHDP and Cl2MDP. It is concluded that high doses of all P-C-Ps inhibit the resorbing osteoclast, but that low dose of the amino P-C-P can specifically inhibit the accession of osteoclast precursors to mineralized matrix. Both actions require P-C-P binding to the mineral. The relative potencies of the P-C-Ps in the precursor-dependent system correspond to their relative potencies in vivo. This suggests that inhibition of accession underlies the high potency which the aminobisphosphonate has in vivo.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3508715

Source DB:  PubMed          Journal:  Bone Miner        ISSN: 0169-6009


  76 in total

1.  Bisphosphonates modulate the expression of OPG and M-CSF in hMSC-derived osteoblasts.

Authors:  Joo-Young Ohe; Yong-Dae Kwon; Hyeon-Woo Lee
Journal:  Clin Oral Investig       Date:  2011-09-22       Impact factor: 3.573

2.  Healing properties of allograft from alendronate-treated animal in lumbar spine interbody cage fusion.

Authors:  Qingyun Xue; Haisheng Li; Xuenong Zou; Mathias Bünger; Niels Egund; Martin Lind; Finn Bjarke Christensen; Cody Bünger
Journal:  Eur Spine J       Date:  2004-07-10       Impact factor: 3.134

3.  Inflammation-mediated osteopenia (IMO): no change in bone resorption during its development.

Authors:  U G Lempert; H W Minne; H Fleisch; R C Mühlbauer; S H Scharla; R Ziegler
Journal:  Calcif Tissue Int       Date:  1991-04       Impact factor: 4.333

4.  Bisphosphonates inhibit the adhesion of breast cancer cells to bone matrices in vitro.

Authors:  G van der Pluijm; H Vloedgraven; E van Beek; L van der Wee-Pals; C Löwik; S Papapoulos
Journal:  J Clin Invest       Date:  1996-08-01       Impact factor: 14.808

5.  Clinical evaluation of incadronate in korean patients with malignancy-associated hypercalcemia: An open-label, multicenter study.

Authors:  Sung-Bae Kim; Jung Shin Lee; Heung Tae Kim; Yong Hyuck Im; Tae Won Kim; Baek Yeol Ryoo; Yeon Hee Park; Joon Oh Park; Keunchil Park; Hitoshi Katoh; Minoru Yamamoto
Journal:  Curr Ther Res Clin Exp       Date:  2007-05

6.  Prospective, mono-institutional study of the impact of a systematic prevention program on incidence and outcome of osteonecrosis of the jaw in patients treated with bisphosphonates for bone metastases.

Authors:  Annalisa Bramati; Serena Girelli; Gabriella Farina; Maria Chiara Dazzani; Valter Torri; Anna Moretti; Sheila Piva; Mariastella Dimaiuta; Nicla La Verde
Journal:  J Bone Miner Metab       Date:  2014-02-20       Impact factor: 2.626

7.  Acid extrusion is induced by osteoclast attachment to bone. Inhibition by alendronate and calcitonin.

Authors:  Z Zimolo; G Wesolowski; G A Rodan
Journal:  J Clin Invest       Date:  1995-11       Impact factor: 14.808

Review 8.  Rationale for the use of alendronate in osteoporosis.

Authors:  J A Kanis; B J Gertz; F Singer; S Ortolani
Journal:  Osteoporos Int       Date:  1995-01       Impact factor: 4.507

9.  Therapeutic efficacy of two different cytostatic-linked phosphonates in combination with razoxane in the transplantable osteosarcoma of the rat.

Authors:  T Klenner; F Wingen; B Keppler; P Valenzuela-Paz; F Amelung; D Schmähl
Journal:  Clin Exp Metastasis       Date:  1990 Jul-Aug       Impact factor: 5.150

10.  Alendronate enhances osteogenic differentiation of bone marrow stromal cells: a preliminary study.

Authors:  Hyung Keun Kim; Ji Hyun Kim; Azlina Amir Abbas; Taek Rim Yoon
Journal:  Clin Orthop Relat Res       Date:  2008-07-30       Impact factor: 4.176

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.